CORCEPT THERAPEUTICS INC (CORT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Product revenue, net | 194,430 | 157,214 | 182,546 | |
| Selling, general and administrative | 103,851 | 90,660 | 73,745 | |
| Research and development | 60,471 | 60,735 | 59,336 | |
| Cost of sales | 3,433 | 2,403 | 2,867 | |
| Total operating expenses | 167,755 | 153,798 | 135,948 | |
| Income from operations | 26,675 | 3,416 | 46,598 | |
| Interest and other income | 5,017 | 6,202 | 6,345 | |
| Income before income taxes | 31,692 | 9,618 | 52,943 | |
| Income tax benefit (expense) | -3,457 | -10,929 | 5,730 | |
| Net income | 35,149 | 20,547 | 47,213 | |
| Basic (in shares) | 104,111,000 | 104,106,000 | 103,371,000 | |
| Basic net income per common share (in dollars per share) | 0.33 | 0.19 | 0.45 | |
| Diluted (in shares) | 120,485,000 | 119,819,000 | 113,723,000 | |
| Diluted net income per common share (in dollars per share) | 0.29 | 0.17 | 0.41 | |